AIIMS Study Backs Funded Flu Vaccines for Indian Seniors

As India’s elderly population grows rapidly, public health experts are advocating for systemic changes to protect vulnerable older adults. A groundbreaking study led by the All India Institute of Medical Sciences (AIIMS), New Delhi, now provides the first concrete evidence backing a government-funded annual flu vaccine for seniors in India. Specifically, this initiative could significantly reduce illness and mortality rates while remaining highly cost-effective.

The Economic Benefits of a Flu Vaccine for Seniors

According to the research, a targeted immunisation programme would deliver substantial economic benefits. While vaccinating all elderly citizens remains cost-effective, prioritising those with chronic conditions is the most viable strategy. Consequently, focusing on individuals with diabetes, heart disease, or chronic lung ailments would cost about Rs 817 crore annually. Conversely, universal vaccination for all seniors would require approximately Rs 1,514 crore.

Unveiling the Hidden Burden of Influenza

Moreover, the researchers highlighted a massive but largely overlooked disease burden among older adults. Every year, influenza causes an estimated 5.3 million illnesses and more than 36,000 hospitalisations in India. Furthermore, the infection leads to nearly 85,000 annual deaths in this age group. Therefore, implementing a public programme is essential to address this silent health crisis. For healthcare providers looking to enhance their ability to treat complex cases in the elderly, exploring Family Medicine Speciality Courses is highly recommended.

Collaborative Research and Data Surveillance

To establish these findings, researchers from several premier Indian institutes collaborated with the US Centers for Disease Control and Prevention. They analysed local clinical data from the robust INSPIRE surveillance network between 2018 and 2023. This network closely followed over 7,200 older adults across four distinct sites in the country. Currently, India has no publicly funded seasonal influenza vaccination programme for its senior population.

Frequently Asked Questions

Q1: Who conducted this cost-effectiveness study on influenza vaccination in India?

The study was led by Prof. Anand Krishnan from AIIMS New Delhi, in collaboration with the Indian Council of Medical Research, the National Institute of Epidemiology, the National Institute of Virology, and the US CDC.

Q2: Why is prioritizing seniors with chronic illnesses considered the best strategy?

This targeted strategy delivers the greatest health gains with the lowest government spending, costing Rs 817 crore compared to Rs 1,514 crore for a universal campaign. Professionals interested in gaining deeper insights into managing metabolic health as part of preventive care can pursue a Certification Course In Diabetes And Metabolic Disorder Care.

References

1. First India study backs govt-funded annual flu vaccine for seniors – ETHealthworld
2. Krishnan A, Prabhakaran AO, Shekhawat K, et al. Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India. Influenza Other Respir Viruses. 2026.
3. Longitudinal Ageing Study in India (LASI). Expert Consensus on Adult Immunisation. Journal of the Indian Academy of Geriatrics. 2026.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.